SLS009 Study: This study is for patients with certain blood cancers, like AML (acute myeloid leukemia) and different types of lymphoma. SLS009 is a special medicine called a CDK9 inhibitor which may help with these types of cancers. The study is checking if SLS009 is safe, how patients handle it, and if it helps fight cancer. There are several groups in this study: some receive SLS009 alone, and others get it with medicines called venetoclax and azacitidine. These medicines are already used to treat some blood cancers.

• The study has different groups and takes place over a period, so patients need to be ready for multiple visits.
• Participants may receive a combination of drugs, which might have side effects or risks.
• Eligibility includes being 18+, with specific health criteria, and for some groups, even kids aged 12-18 can join.